H3N2v and Other Influenza Epidemic Risk Based on Age-Specific Estimates of Sero-Protection and Contact Network Interactions

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Skowronski, Danuta M ^a,b   Moser, Flavia S ^a   Janjua, Naveed Z ^a,b   Davoudi, Bahman ^b   English, Krista M ^b   Purych, Dale ^c   Petric, Martin ^a,b   Pourbohloul, Babak ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC Biomedical Laboratories Ltd   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; BASIC REPRODUCTION NUMBER; CANADA; CHILD; CONTROLLED STUDY; EPIDEMIC; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA A (H3N2); MAJOR CLINICAL STUDY; NONHUMAN; PANDEMIC; PRESCHOOL CHILD; RISK ASSESSMENT; SCHOOL CHILD; SEASONAL INFLUENZA; SEASONAL VARIATION; SOCIAL INTERACTION; VIRUS DETECTION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; AGE FACTORS; ANIMALS; ANTIBODIES, VIRAL; CANADA; CHILD; CHILD, PRESCHOOL; EPIDEMICS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; RISK ASSESSMENT; SEROTYPING; SWINE;

SUIDAE;

EID: 84872252420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054015     Document Type: Article

References (61)

1. Cox RJ, Brokstad KA, Ogra P, (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
2. Scholtissek C, Hinshaw VS, Olsen CV (1998) Influenza in pigs and their role as intermediate host. In: Nicholson KG, Webster KG, Hay A, editors. Textbook of Influenza. Oxford, UK: Blackwell Science. 137-145.
3. Potter CW (1998) Chronicle of influenza pandemics. In: Nicholson KG, Webster KG, Hay A, editors. Textbook of Influenza. Oxford, UK: Blackwell Science. 3-18.
4. Belshe RB, (2005) The origins of pandemic influenza-lessons from the 1918 virus. N Engl J Med 353: 2209-2211.
5. Smith GJD, Bahl J, Vijaykrishna D, Zhang J, Poon LLM, et al. (2009) Dating the emergence of pandemic influenza viruses. PNAS 106: 11709-11712.
6. Zimmer SM, Burke DS, (2009) Historical perspective-emergence of influenza A (H1N1) viruses. NEJM 361: 279-285.
7. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325(5937): 197-201 DOI: 10.1126/science. 1176225.
8. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, et al. (2011) Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 203: 158-167. Available: http://jid.oxfordjournals.org/content/203/2/158.full.pdf. Accessed 2012 September 26.
9. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15(5): pii: 19478.
10. Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, et al. (2010) Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 28(20): 3558-3562.
11. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr H, (2010) Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 199: 117-121.
12. Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, et al. (2010) High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill 15(31): pii: 19633. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19633. Accessed 2012 September 26.
13. Hardelid P, Andrews N, Hoschler K, Stanford E, Baguelin M, et al. (2010) Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A H1N1 2009. Health Technol Assess 14(55): 115-192.
14. Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, et al. (2011) Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 6(6): e21340.
15. Achonu C, Rosella L, Gubbay JB, Deeks S, Rebbapragada A, et al. (2011) Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010. PLoS One 6(11): e26427.
16. Skowronski DM, Hottes TS, Janjua NZ, Purych D, Sabaiduc S, et al. (2010) Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ 182: 1851-1856. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988533/pdf/1821851.pdf. Accessed 2012 September 26.
17. Steens A, Waaijenborg S, Teunis PF, Reimerink JH, Meijer A, et al. (2011) Age-dependent patterns of infection and severity explaining the low impact of 2009 influenza A (H1N1): evidence from serial serologic surveys in the Netherlands. Am J Epidemiol 174(11): 1307-1315.
18. Ross TM, Hairong K, Chia BS, Hill E, Weirback H, et al. (2011) Prevalence of antibodies against seasonal influenza A and B viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USA. PLoS Curr 3: RRN1265. Available: http://currents.plos.org/influenza/article/prevalence-of-antibodies-against-12llkqqk4m6bk-10/. Accessed 2012 September 26.
19. BC Centre for Disease Control. Influenza Surveillance Reports. Available: http://www.bccdc.ca/dis-cond/DiseaseStatsReports/influSurveillanceReports.htm. Accessed 2012 September 26.
20. Public Health Agency of Canada. FluWatch. Available: http://www.phac-aspc.gc.ca/fluwatch/. Accessed 2012 September 26.
21. National Advisory Committee on Immunization. (2012) Statement on seasonal influenza vaccine for 2012-2013. Available: http://resources.cpha.ca/immunize.ca/data/1814e.pdf Accessed 2012 September 26.
22. Centers for Disease Control and Prevention. Fluview 2010-2011 influenza season Summary. Available: http://www.cdc.gov/flu/weekly/weeklyarchives2010-2011/10-11summary.htm. Accessed 2012 September 26.
23. Centers for Disease Control and Prevention (2012) Update: influenza activity - United States, 2011-12 season and composition of the 2012-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 61(22): 414-420. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6122a4.htm Accessed 2012 September 26.
24. Centers for Disease Control and Prevention (2011) Swine-origin influenza A (H3N2) virus infection in two children-Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 60: 1213-1215.
25. Centers for Disease Control and Prevention (2012) Update: influenza A (H3N2)v transmission and guidelines-five states, 2011. MMWR Morb Mortal Wkly Rep 60: 1741-1744.
26. Wong KK, Greenbaum A, Moll ME, Lando J, Moore EL, et al. (2012) Outbreak of influenza A (H3N2) variant virus infection among attendees of an agricultural fair, Pennsylvania, USA, 2011. Emerg Infect Dis. DOI: 10.3201/eid1812.121097 http://dx.doi.org/10.3201/eid1812.121097 Accessed 2012 September 26.
27. Lindstrom S, Garten R, Balish A, Shu B, Emery S, et al. (2012) Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis. DOI: 10.3201/eid1805.111922 Available at: http://dx.doi.org/10.3201/eid1805.111922 Accessed 2012 September 26.
28. Centers for Disease Control and Prevention (2012) First H3N2 variant virus infection reported for 2012. Available: http://www.cdc.gov/flu/spotlights/h3n2v-variant-utah.htm Accessed 2012 September 26.
29. World Health Organization (2011) Standardization of terminology for the variant A(H3N2) virus recently infecting humans. Joint Announcement of FAO, OIE and WHO. Geneva: WHO. Available: http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/en/index.html Accessed 2012 September 26.
30. Pearce MB, Jayaraman A, Pappas C, Belser JA, Zeng H, et al. (2012) Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferrets. Proc Natl Acad Sci U S A 109: 3944-3949.
31. Centers for Disease Control and Prevention (2012). Influenza A (H3N2) variant virus outbreaks. Available: http://www.cdc.gov/flu/swineflu/h3n2v-outbreak.htm Accessed 2012 September 26.
32. Lina B, Bouscambert M, Enouf V, Rousset D, Valette M, et al. (2011) S-OtrH3N2 viruses: use of sequence data for description of the molecular characteristics of the viruses and their relatedness to previously circulating H3N2 human viruses. Euro Surveill 16(50): pii: 20039. Available: http://www.eurosurveillance.org/ViewArticle.aspx?Articleid=20039 Accessed 2012 September 26.
33. Skowronski DM, De Serres G, Janjua NZ, Gardy JL, Gilca V, et al. (2012) Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunization with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. Euro Surveill 17(4): pii: 20066. Available: http://www.eurosurveillance.org/ViewArticle.aspx?Articleid=20066 Accessed 2012 September 26.
34. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, et al. (2012) Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis [Epub ahead of print]. DOI: 10.1093/infdis/jis500. Available: http://jid.oxfordjournals.org/content/early/2012/09/06/infdis.jis500.long Accessed 2012 September 26.
35. Centers for Disease Control and Prevention (2012) Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States. MMWR Morb Mortal Wkly Rep 61: 237-241. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6114a1.htm?s_cid=mm6114a1_w Accessed 2012 September 26.
36. Waalen K, Kilander A, Dudman S, Ramos-Ocao R, Hungnes O (2012) Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill 17(19): pii: 20170. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20170 Accessed 2012 September 26.
37. Mikolajczyk RT, Akmatov MK, Rastin S, Kretzschmar M, (2008) Social contacts of school children and the transmission of respiratory-spread pathogens. Epidemiol Infect 136: 813-822.
38. Nguyen-Van-Tam JS (1998) Epidemiology of influenza. In: Nicholson KG, Webster RG, Hays AJ, editors. Textbook of Influenza. Malden, MA: Blackwell Science. 181-206.
39. Pourbohloul B, Meyers LA, Skowronski DM, Krajden M, Patrick D, et al. (2005) Modeling control strategies of respiratory pathogens. Emerg Infect Dis 11: 1249-1256.
40. Meyers LA, Pourbohloul B, Newman ME, Skowronski DM, Brunham RC, (2005) Network theory and SARS: predicting outbreak diversity. J Theor Biol 232: 71-81.
41. Meyers LA, Newman ME, Pourbohloul B, (2006) Predicting epidemics on directed contact networks. J Theor Biol 240: 400-418.
42. Bansal S, Pourbohloul B, Meyers LA, (2006) A comparative analysis of influenza vaccination programs. PLoS Med 3(10): e387.
43. Bansal S, Pourbohloul B, Hupert N, Grenfell B, Meyers LA, (2010) The shifting demographic landscape of pandemic influenza. PLoS One 5: e9360.
44. Conway JM, Tuite AR, Fisman DN, Hupert N, Meza R, et al. (2011) Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. BMC Public Health 11: 932. Available: http://www.biomedcentral.com/1471-2458/11/932 Accessed 2012 September 26.
45. Fraser C, Riley S, Anderson R, Ferguson N, (2005) Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 101: 6146-6151.
46. World Health Organization. WHO recommendations on the composition of influenza virus vaccines. Available: http://www.who.int/influenza/vaccines/virus/recommendations/en/index.html Accessed 2012 September 26.
47. World Health Organization Global Influenza Surveillance Network (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. Available: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf Accessed 2012 September 26.
48. Committee for Proprietary Medicinal Products [CPMP] (1997) Note for guidance on harmonization of requirements for influenza vaccines. London: European Agency for the Evaluation of Medicinal Products. CPMP/BWP/214/96(circular no. 96-0666): 1-22.
49. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
50. Katz JM, Hancock K, Xu X, (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9: 669-683.
51. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press. 757 p.
52. Tuite AR, Greer AL, Whelan M, Winter AL, Lee B, et al. (2010) Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. CMAJ. 182(2): 131-136.
53. Longini IM Jr, Nizam A, Xu S, (2005) Containing pandemic influenza at the source. Science 309: 1083-1087.
54. Pourbohloul B, Ahued A, Davoudi B, Meza R, Meyers LA, et al. (2009) Initial human transmission dynamics of the pandemic (H1N1) 2009 virus in North America. Influenza Other Respi Viruses 3(5): 215-222 DOI: 10.1111/j.1750-2659.2009.00100.x Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122129/?tool=pubmed Accessed 2012 September 26.
55. Matrajt L, Longini IM, (2012) Critical immune and vaccination thresholds for determining multiple influenza epidemic waves. Epidemics 4: 22-32.
56. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, for the H1N1pdm Serology Working Group (2013) Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza and Other Respiratory Viruses [In press].
57. Nicholson KG (1998) Human influenza. In: Nicholson KG, Webster RG, Hays AJ, editors. Textbook of Influenza. Malden, MA: Blackwell Science. 221-226.
58. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
59. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
60. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, et al. (2011) Hemagglutination inhibition antibody titers as a correlate of protection for inactivated trivalent influenza vaccines in children. Pediatr Infect Dis J 30: 1081-1085.
61. Hethcote HW, (2000) The Mathematics of Infectious Diseases. SIAM Rev Soc Ind Appl Math 42(4): 599-653.